Antibodies
5 November 2015
Halozyme Announces First Clinical Dosing Of Janssen’s Daratumumab Using ENHANZE™ Technology3 November 2015
Kadmon Corporation Presents Preclinical Data on Immuno-Oncology Anti-PD-L1/IL-15 Fusion Protein at AACR-NCI-EORTC Symposium30 October 2015
Bayer Receives EU Approval for EYLEA® for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization28 October 2015
Boehringer Ingelheim’s Biosimilar Candidate Demonstrated Pharmacokinetic Bioequivalence to Adalimumab28 October 2015
Celltrion Healthcare: No difference in efficacy or immunogenicity following switch to Remsima®▼ (infliximab) from originator26 October 2015
XOMA Initiates Proof-of-Concept Study for XOMA 358 in Patients with Congenital Hyperinsulinism21 October 2015
Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS20 October 2015
Immunomedics Reports Durable Responses in Patients With Advanced Solid Cancers After Therapy With Sacituzumab Govitecan19 October 2015
Pfizer’s Inotuzumab Ozogamicin Receives FDA Breakthrough Therapy Designation for Acute Lymphoblastic Leukemia (ALL)19 October 2015
Phase 3 Data Show STELARA® Induced Clinical Response And Remission In The Treatment Of Patients With Moderate To Severe Crohn’s DiseaseNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports